مباشر
Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsFierceBiotechBiopharma moves to reduce development risk earlier than everFierceBiotechIncyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaEndpoints News#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotFierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection pointFierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regressionLabiotechTop biotech deals in May 2026PharmaVoice3 potential takeover targets in obesityFierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-making
Endpoints News ١٩ ديسمبر ٢٠٢٥

Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.